Spinal cord stimulation

Series
Neuromodulation
Status
Published
Date
Number of report
037

Ask the expert

(we accept only company emails)

The report presents a summary of the reimbursement situation for use of spinal cord stimulation. Indications include neuropathic and ischemic pain.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

Clinical scenarios include trial insertion of electrodes and external stimulator, permanent implantation of spinal cord stimulator, adjustment/programming of stimulator, removal of stimulator, and replacement of battery of pulse generation.

The only reimbursement within public / statutory health insurance systems is considered.

The report includes essential information about reimbursement, including:

  • Brief country-specific overview of reimbursement system
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions on indications or scenarios for the use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • Finland
  • France
  • Germany
  • Italy
  • The Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of the spinal cord stimulation devices include:

  • Boston Scientific (Precision)
  • Nevro (Senza)
  • Stimwave (Freedom SCS)
  • Abbot Vascular (BurstDR: Proclaim, Prodigy MRI IPG, St. Jude Medical Invisible Trial System; Eon)
  • Medtronic (Intellis; SureScan: RestoreSenso, RestoreUltra, RestoreAdvanced, PrimeAdvanced)
  • Saluda Medical (Evoke SCS System)
  • Nuvectra (Algovita SCS)
  • Med-Ally (VersaStim IPG Platform)

Table of content is not available at this moment.

17

Nov 2022

In November 2022, an annual update of the Swedish procedure coding system (Classification of Health Care Measures, KVÅ) was released to come into force from January 2023. A total of 119 new surgical procedure codes and 98 new medical procedure codes will be introduced concerning cardiovascular, diagnostic imaging, eHealth, endocrinology, endoscopy, ENT, gastrointestinal, IVD, nephrology and urology, peripheral vascular, and others.

Read more

08

Nov 2022

In October 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (YAG laser vitreolysis for symptomatic vitreous floaters, transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine), one Medical Technologies Guidance (Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer) and three new Medtech Innovation Briefings (O2matic PRO 100, Daylight, Signatera). Also, one new clinical guideline was published on osteoarthritis.

Read more

17

Oct 2022

Swedish Medical Technologies Product (MTP) Council is currently evaluating devices for spinal cord stimulation (SCS) as part of the Orderly introduction framework, a staged process aimed at managing the national introduction of novel technologies. On September 23, 2022, MTP Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic evaluation of five SCS devices. Based on the TLV assessment, MTP Council will make recommendations to regions regarding the introduction of SCS devices and the criteria for use.

Read more

07

Oct 2022

On September 22, 2022, the Austrian version of the DRG system (LKF) 2023 model with the relevant supplementary documents was published in Austria. The document "Changes and innovations in the 2023 LKF model" summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes mainly concern cardiovascular, extracorporeal treatments, and peripheral vascular fields.

Read more

06

Oct 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in September 2022. Thirty-eight recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular and peripheral vascular, neurovascular and neuromodulation, orthopedic, endocrine, ENT, dermatological, and spine-related devices, as well as digital care and medical aids.

Read more
(we accept only company emails)